Reconciliation Software for Indian Pharmaceutical Manufacturers

A pharma reconciliation platform built for India ties together nine sector-specific surfaces that no horizontal accounting or generic reconciliation tool covers natively: (1) the 22-September-2025 GST 2.0 transition where the 56th GST Council meeting of 3-September-2025 moved all drugs to a flat 5 percent rate, medical devices under HSN 9018-9022 from 18 percent to 5 percent, and life-saving drugs (specified schedule of cancer, HIV, TB, and rare-disease drugs) to nil rate; (2) Rule 89(5) inverted-duty refund under Section 54(3) of the CGST Act 2017, deepened structurally by the 22-September-2025 rate cut and further constrained by CBIC Notification 14/2022-CT dated 5-July-2022 which excludes input services and capital goods from the net-ITC formula; (3) the API vs formulation HSN split across Chapter 29 (2941 antibiotics as APIs) and Chapter 30 (3003 non-formulation bulk drugs, 3004 finished dosage forms) with backward-integrated intra-group transfer pricing under Section 92BA Rule 10D; (4) USFDA Form 483 observation remediation cost accounting, including Ind AS 37 provision recognition on receipt of a Warning Letter, Ind AS 115 revenue constraint under Import Alert 89-08 for a plant, and Section 37 deductibility of remediation consulting from Lachman Consultant Services or Parexel Consulting style firms; (5) PLI Pharma Rs 15,000 crore incremental-sales claim on the DoP portal against a FY 2019-20 base across three categories (complex generics / patented drugs / cell and gene therapy / orphan drugs; APIs and KSMs and Drug Intermediates; IVDs and repurposed drugs and medical devices); (6) Section 35(2AB) 100 percent weighted deduction for in-house R&D at a DSIR-approved facility, with the Form 3CM approval, Form 3CL year-end quantum and Form 3CLA return-schedule cascade; (7) generic export markets across ANDA milestone recognition and DGFT RoDTEP + Drawback + Advance Authorisation stacking; (8) loan-licensing manufacturing under Section 143 CGST + Rule 45 + ITC-04 quarterly return where inputs are sent to a third-party manufacturer without payment of tax; and (9) DPCO 2013 Para 20 overcharging recovery mechanism for NLEM scheduled formulations at ceiling prices notified by the National Pharmaceutical Pricing Authority.

The 56th GST Council meeting on 3-September-2025 was a landmark rate-rationalisation for pharma. Effective 22-September-2025: all drugs were moved to a flat 5 percent GST rate, medical devices under HSN 9018-9022 (medical instruments and apparatus, diagnostic devices, X-ray, ECG, dental instruments) dropped from 18 percent to 5 percent, and a specified schedule of life-saving drugs across cancer, HIV, TB and rare-disease categories moved to nil rate. GST Council FAQ Q10, Q25 and Q51 explicitly acknowledged that the inverted-duty structure would deepen and pledged expedited Section 54(3) refund processing. For any pharma manufacturer this creates four concurrent reconciliation loads. First, a straddle-invoice exercise under Section 15 CGST for goods dispatched pre-22-Sept-2025 but received (or invoiced under time-of-supply rules) post-22-Sept-2025 — every straddle case must be classified against the correct rate. Second, medical devices manufacturers moving from 18 percent to 5 percent output face a step-change in Rule 89(5) accumulation (packaging, sterilisation consumables, capital goods GST does not step down). Third, life-saving nil-rate drugs create Rule 42 and Rule 43 common-credit reversal exposure — where the same inputs feed both taxable and exempt supplies, proportional reversal must be computed and reconciled monthly. Fourth, the pre-cutover WIP inventory and finished-goods stock physically at plants, C&F agents and stockists on the night of 21-22-Sept-2025 must be revalued for MRP compliance under DPCO 2013 and for output-tax rate application on subsequent invoicing. TransactIG ingests every straddle invoice, ties time-of-supply to the correct pre/post rate, computes Rule 42/43 monthly reversal on nil-rate drugs, and produces the GST Council FAQ Q10/Q25/Q51 audit reading pack.

Section 54(3) of the CGST Act 2017 allows refund of unutilised Input Tax Credit accumulated on account of inverted duty structure — where the output GST rate is lower than the input GST rate. Rule 89(5) prescribes the formula. Post the 22-September-2025 rate cut, Rule 89(5) is central to pharma cash flow because the output rate for formulations dropped to 5 percent (nil for life-saving) while packaging materials, laboratory consumables, capital goods, utilities, and most input services remain at 18 percent. This structural inversion is not a temporary phenomenon — it is a permanent feature of the new pharma rate table. However, two constraints apply. First, CBIC Notification 14/2022-CT dated 5-July-2022 amended the Rule 89(5) formula prospectively: applications on or after 5-July-2022 use net-ITC excluding input services and capital goods, applications prior use the pre-amendment formula. Union of India v. VKC Footsteps (2021) 10 SCC 674 upheld this legislative competence. Second, CBIC Notification 09/2022-CT (Rate) dated 13-July-2022, effective 18-July-2022, invoked clause (ii) of the first proviso to Section 54(3) to BAR refund of unutilised ITC on Inverted Duty Structure for goods under HSN Chapter 27 (mineral fuels, mineral oils, distillation products). This directly affects API manufacturers whose input basket includes hexane, isopropyl alcohol, methanol, toluene and methyl ethyl ketone (MEK) — solvents used in fermentation, extraction, and synthesis. The ITC on these Chapter 27 solvents accumulated against a 5 percent output is a permanent P&L loss, not a claimable refund. TransactIG classifies every inbound invoice by HSN chapter, separates claimable inversion (packaging, non-Chapter-27 chemicals, laboratory glassware) from blocked Chapter 27 solvent ITC, runs the amended net-ITC formula for RFD-01 filed on or after 5-July-2022, and produces the monthly refund pack with the correct formula version and the Chapter 27 permanent-loss quantification separately.

USFDA plant inspections generate three escalating instruments: Form 483 observations (issued at close of inspection), Warning Letter (if 483 responses inadequate), and Import Alert 89-08 (bars entry of specified products from the plant into the US market). Each has a distinct financial-reporting consequence. Under Ind AS 37 (Provisions, Contingent Liabilities, Contingent Assets), a Warning Letter typically creates a constructive obligation for remediation — the entity has a reliable estimate of the outflow required to restore CGMP compliance (consulting fees, capital expenditure on facility upgrades, retraining, revalidation batches). Provision recognition and disclosure become mandatory at each reporting date, with re-measurement as the remediation programme progresses. Under Ind AS 115 (Revenue from Contracts with Customers), an Import Alert 89-08 constrains revenue recognition from that plant to the US market — until the alert is lifted, the entity cannot recognise revenue on shipments to US customers because collection is not probable. This drives a step-change in ANDA (Abbreviated New Drug Application) milestone revenue timing. On the deductibility side, Section 37 of the Income-tax Act 2025 (wholly-and-exclusively-for-business test) supports deductibility of remediation costs paid to CGMP consulting firms — Lachman Consultant Services, Parexel Consulting style engagements — provided the expenditure is genuine business expense and not capital in nature. Foreign consulting fees trigger Section 195 TDS on remittance at the applicable DTAA rate. Consulting fees to Indian consultants trigger Section 194J code 1005 professional-fees TDS at 10 percent. TransactIG ties the 483 observation to the remediation project charter, projects the Ind AS 37 provision quantum against a reliable estimate methodology, flags Import Alert 89-08 plants for the Ind AS 115 constraint on US-market revenue recognition, and produces the 194J code 1005 and Section 195 TDS reconciliation pack for both domestic and foreign remediation consultants.

The Rs 15,000 crore PLI Pharma scheme run by the Department of Pharmaceuticals covers three categories with a 6-year incentive window against an FY 2019-20 base year: Category 1 (complex generics, patented drugs, cell and gene therapy, orphan drugs), Category 2 (Active Pharmaceutical Ingredients, Key Starting Materials, Drug Intermediates), and Category 3 (in-vitro diagnostic devices, repurposed drugs, medical devices, other drugs not covered in Cat 1/2). Incentive is calculated on incremental sales over the FY 2019-20 base, claimed quarterly on the DoP portal. This is separate from the Rs 6,940 crore PLI Bulk Drug scheme covering 53 critical APIs and KSMs on fermentation and chemical-synthesis basis. Section 35(2AB) of the Income-tax Act 1961 (continued as Section 35(2AB) IT Act 2025) provides 100 percent weighted deduction for in-house R&D expenditure at a DSIR-approved facility (the weighted rate was 200 percent till FY 2016-17, 150 percent till FY 2019-20, 100 percent thereafter). The Form 3CM approval, Form 3CL year-end quantum certification and Form 3CLA return schedule cascade is administered by the Department of Scientific and Industrial Research under guidelines DSIR/Sec35(2AB)/1/2021. Loan-licensing manufacturing operates under Section 143 CGST + Rule 45 + ITC-04 quarterly return — a brand owner sends inputs to a third-party manufacturer (contract development and manufacturing organisation) without payment of tax; the inputs must be returned as goods within 1 year (or capital goods within 3 years) or the transaction is deemed a supply. Loan-licensee is typically an MSME, triggering Section 43B(h) 45-day payment discipline. Ind AS 38 requires a book-tax reconciliation gap for R&D — development-phase R&D is capitalised subject to a 6-condition test while research-phase is expensed, but Section 35(2AB) allows the tax-book weighted deduction on revenue expenditure. Section 115BAA opt-in for the 22 percent concessional corporate tax rate surrenders Section 35(2AB) — this is a strategic reconciliation decision. Section 115JB MAT at 15 percent of book profit interacts with PLI grant income taxability and book-profit adjustment. TransactIG ties PLI quarterly incremental-sales claim by category to the audited FY 2019-20 base, ties Section 35(2AB) R&D expenditure by DSIR-approved facility to Form 3CM/3CL/3CLA cascade, and ties loan-licensing input dispatch to ITC-04 quarterly filing with the 1-year/3-year return clock — all on a single ingest, single variance taxonomy, single audit pack.